Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Summer;24(2):108-117.
doi: 10.31486/toj.23.0074.

At a Crossroads: Opioid Use Disorder, the X-Waiver, and the Road Ahead

Jaskaran Singh Dhillon  1 , Leah Feulner  1 , Ariya Beitollahi  1 , Kelly Kossen  1 , David Galarneau  1   2
Affiliations
Review

At a Crossroads: Opioid Use Disorder, the X-Waiver, and the Road Ahead

Jaskaran Singh Dhillon et al. Ochsner J. 2024 Summer.

Abstract

Background: Buprenorphine/naloxone (Suboxone) is widely considered the first-line treatment for opioid use disorder (OUD), which causes significant morbidity and mortality in the United States, but prior to 2023, practitioners interested in prescribing buprenorphine/naloxone for OUD needed a special Drug Enforcement Administration certification (the X-Waiver) that imposed a patient cap and other limitations. The Consolidated Appropriations Act of 2023 considerably decreased the restrictions on prescribing practitioners. Buprenorphine/naloxone can now be prescribed like any other prescription opioid, excluding methadone. The historic context for the opioid crisis, OUD, the X-Waiver, and additional initiatives that may be needed beyond legislative change to effectively address OUD are the subjects of this review. Methods: To develop this review of the opioid crisis, OUD, and OUD treatment, we conducted a literature search of the PubMed database and constructed a timeline of the opioid crisis and changes in OUD treatment, specifically the X-Waiver, to characterize the historic context of OUD and the X-Waiver against the background of the opioid crisis. Results: The opioid crisis has had pervasive public health and economic impacts in the United States. Major changes to the treatment of OUD have occurred as a result of the Drug Addiction Treatment Act of 2000 that imposed the X-Waiver and the Consolidated Appropriations Act of 2023 that repealed the X-Waiver. Conclusion: The repeal of the X-Waiver is predicted to increase the accessibility of buprenorphine/naloxone in the United States. However, additional work beyond legislative change, including institutional support and reduction of stigma and disparities, is needed to substantially improve outcomes for OUD patients.

Keywords: Addiction medicine; analgesics–opioid; buprenorphine–naloxone drug combination; opioid-related disorders; psychiatry.

PubMed Disclaimer

References

    1. Taylor JL, Samet JH. Opioid use disorder. Ann Intern Med. 2022;175(1):ITC1-ITC16. doi: 10.7326/AITC202201180 - DOI - PubMed
    1. Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82-88. doi: 10.1016/j.biopsych.2019.06.020 - DOI - PubMed
    1. Hoffman KA, Ponce Terashima J, McCarty D. Opioid use disorder and treatment: challenges and opportunities. BMC Health Serv Res. 2019;19(1):884. doi: 10.1186/s12913-019-4751-4 - DOI - PMC - PubMed
    1. Keyes KM, Rutherford C, Hamilton A, et al. . What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3:100052. doi: 10.1016/j.dadr.2022.100052 - DOI - PMC - PubMed
    1. National Center for Injury Prevention and Control: Opioid Basics. Understanding the opioid overdose epidemic. Centers for Disease Control and Prevention. Updated August 8, 2023. Accessed March 7, 2023. cdc.gov/opioids/basics/epidemic.html

LinkOut - more resources